Houstonians live well. Photo via Getty Images

A new economic analysis by the Ludwig Institute for Shared Economic Prosperity (LISEP) has revealed that Houston-The-Woodlands-Sugar Land has the 30th most prosperous local economy in the nation. The analysis ranked the 50 largest Metropolitan Statistical Areas (MSAs) in the U.S. based on several localized economic factors.

According to Houston's data, the region's population has skyrocketed 18.7 percent within the last decade, now reaching over 7.34 million people. The median age of an Houston-area resident is 35.1-years-old.

The three main criteria that determined Houston's prospering rank include a "True Living Cost" metric that tracks price changes for essential household necessities; a "True Weekly Earnings" calculation that determines the median weekly earnings of all workers (including part-timers and those who are unemployed); and a "True Rate of Unemployment Out of the Population" metric that measures the percentage of people unable to find full-time employment with a living wage.

The findings show that a little more than half of all Houston-area households are earning enough income to afford their basic needs. The remaining 46.4 percent are struggling due to a high cost of living, the report said.

"The total costs of necessities for a 4-person family [in Houston-The Woodlands-Sugar Land] increased 58.2 percent since 2005 from $54,052 to $85,492," the report said.

Furthermore, Houstonians are bringing home higher weekly earnings than they were in 2020. Houston workers are earning a median $894.89 per week, or about $47,429.17 a year. The report states the average employee has gained 8.2 percent more purchasing power since 2005, and the average Houston household has 8.1 percent of their income leftover after their necessities.

Houston's "True Rate of Unemployment Out of the Population" is 63 percent, according to the analysis.

The objective behind LISEP's report is to help policymakers assess their local economies' dynamics and to assess how much low-income and working-class families are affected, according to LISEP Chairman Gene Ludwig in the release.

"Across the nation we are seeing both ends of the spectrum — communities where middle- and working-class families are faring well and others where financial survival remains a struggle," Ludwig said. "Our challenge here is in identifying what's working well and replicating it; what's not, and scrapping it. This is where real-world data can be invaluable to policymakers."

Houston-The Woodlands-Sugar Land wasn't the only Texas metro area to earn a spot in the analysis. Austin-Round Rock worked its way up into No. 2 nationally, while San Antonio-New Braunfels ranked just outside the top 10 at No. 13. Dallas-Fort Worth-Arlington ranked four spots higher than Houston at No. 26.

The top 10 highest-performing economies in the U.S. are:

  • No. 1 – San Jose-Sunnyvale, Santa Clara, California
  • No. 2 – Austin-Round Rock, Texas
  • No. 3 – San Francisco-Oakland-Hayward, California
  • No. 4 – Baltimroe-Columbia-Towson, Maryland
  • No. 5 – Washington-Arlington-Alexandria, District of Columbia-Virginia-Maryland
  • No. 6 – Minneapolis-St. Paul-Blookington, Minnesota-Wisconsin
  • No. 7 – Portland-Vancouver-Hillsboro, Oregon-Washington
  • No. 8 – Milwaukee-Waukesha-West Allis, Wisconsin
  • No. 9 – Denver-Aurora-Lakewood, Colorado
  • No. 10 – Salt Lake City, Utah
The full report and its methodology can be found on lisep.org.

------

This article originally ran on CultureMap.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Axiom Space-tested cancer drug advances to clinical trials

mission critical

A cancer-fighting drug tested aboard several Axiom Space missions is moving forward to clinical trials.

Rebecsinib, which targets a cancer cloning and immune evasion gene, ADAR1, has received FDA approval to enter clinical trials under active Investigational New Drug (IND) status, according to a news release. The drug was tested aboard Axiom Mission 2 (Ax-2) and Axiom Mission 3 (Ax-3). It was developed by Aspera Biomedicine, led by Dr. Catriona Jamieson, director of the UC San Diego Sanford Stem Cell Institute (SSCI).

The San Diego-based Aspera team and Houston-based Axiom partnered to allow Rebecsinib to be tested in microgravity. Tumors have been shown to grow more rapidly in microgravity and even mimic how aggressive cancers can develop in patients.

“In terms of tumor growth, we see a doubling in growth of these little mini-tumors in just 10 days,” Jamieson explained in the release.

Rebecsinib took part in the patient-derived tumor organoid testing aboard the International Space Station. Similar testing is planned to continue on Axiom Station, the company's commercial space station that's currently under development.

Additionally, the drug will be tested aboard Ax-4 under its active IND status, which was targeted to launch June 25.

“We anticipate that this monumental mission will inform the expanded development of the first ADAR1 inhibitory cancer stem cell targeting drug for a broad array of cancers," Jamieson added.

According to Axiom, the milestone represents the potential for commercial space collaborations.

“We’re proud to work with Aspera Biomedicines and the UC San Diego Sanford Stem Cell Institute, as together we have achieved a historic milestone, and we’re even more excited for what’s to come,” Tejpaul Bhatia, the new CEO of Axiom Space, said in the release. “This is how we crack the code of the space economy – uniting public and private partners to turn microgravity into a launchpad for breakthroughs.”

Chevron enters the lithium market with major Texas land acquisition

to market

Chevron U.S.A., a subsidiary of Houston-based energy company Chevron, has taken its first big step toward establishing a commercial-scale lithium business.

Chevron acquired leaseholds totaling about 125,000 acres in Northeast Texas and southwest Arkansas from TerraVolta Resources and East Texas Natural Resources. The acreage contains a high amount of lithium, which Chevron plans to extract from brines produced from the subsurface.

Lithium-ion batteries are used in an array of technologies, such as smartwatches, e-bikes, pacemakers, and batteries for electric vehicles, according to Chevron. The International Energy Agency estimates lithium demand could grow more than 400 percent by 2040.

“This acquisition represents a strategic investment to support energy manufacturing and expand U.S.-based critical mineral supplies,” Jeff Gustavson, president of Chevron New Energies, said in a news release. “Establishing domestic and resilient lithium supply chains is essential not only to maintaining U.S. energy leadership but also to meeting the growing demand from customers.”

Rania Yacoub, corporate business development manager at Chevron New Energies, said that amid heightening demand, lithium is “one of the world’s most sought-after natural resources.”

“Chevron is looking to help meet that demand and drive U.S. energy competitiveness by sourcing lithium domestically,” Yacoub said.

---

This article originally appeared on EnergyCapital.